APG Asset Management N.V. Sells 45,951 Shares of Boston Scientific Corporation $BSX

APG Asset Management N.V. decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 4.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 975,266 shares of the medical equipment provider’s stock after selling 45,951 shares during the period. APG Asset Management N.V.’s holdings in Boston Scientific were worth $91,080,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Y.D. More Investments Ltd bought a new stake in Boston Scientific during the 1st quarter worth $27,000. Investment Management Corp VA ADV bought a new stake in Boston Scientific during the 4th quarter worth $25,000. Colonial Trust Co SC grew its position in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 260 shares during the last quarter. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the 4th quarter worth $26,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the 4th quarter worth $31,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.7%

Shares of NYSE:BSX opened at $105.9950 on Friday. The business’s 50-day moving average is $104.10 and its 200-day moving average is $102.16. Boston Scientific Corporation has a 1 year low of $78.53 and a 1 year high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $157.06 billion, a price-to-earnings ratio of 63.09, a P/E/G ratio of 2.53 and a beta of 0.66.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the business earned $0.62 EPS. The firm’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research reports. Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Needham & Company LLC reiterated a “buy” rating and issued a $115.00 price target on shares of Boston Scientific in a research report on Wednesday, May 28th. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. UBS Group upped their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Finally, Citigroup reiterated a “buy” rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $117.50.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 in the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.